Targets › RDCVF
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Feb 2027.
Open in Phaseline: the race on RDCVF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SparingVision | SPVN06 AAV-delivered RdCVF-RdCVFL gene therapy | RDCVF | Phase 1 | Retinitis Pigmentosa | Feb 2027 |
Retinitis Pigmentosa (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.